Allakos 관리

관리 기준 확인 3/4

Allakos CEO는 Robert Alexander, Apr2017 에 임명되었습니다 의 임기는 7.58 년입니다. 총 연간 보상은 $ 6.30M, 12.8% 로 구성됩니다. 12.8% 급여 및 87.2% 보너스(회사 주식 및 옵션 포함). 는 $ 623.71K 가치에 해당하는 회사 주식의 0.8% 직접 소유합니다. 623.71K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 6.4 년입니다.

주요 정보

Robert Alexander

최고 경영자

US$6.3m

총 보상

CEO 급여 비율	12.8%
CEO 임기	7.6yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	6.4yrs

최근 관리 업데이트

Recent updates

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 04

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Oct 18

Allakos prices ~$150M underwritten offering

Sep 19

Allakos falls as lead asset offers mixed results in late-stage trial

Sep 09

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Aug 06

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Apr 22

Allakos: Sad End To A Promising Asset

Dec 23

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Dec 01

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Aug 16

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

Aug 06

Allakos provides lirentelimab clinical trial enrollment updates, names new CMO

Jun 07

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

May 02

Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?

Mar 10

Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling

Jan 28

We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow

Dec 07

Allakos EPS misses by $0.02

Nov 09

CEO 보상 분석

Robert Alexander 의 보수는 Allakos 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$179m
Jun 30 2024	n/a	n/a	-US$206m
Mar 31 2024	n/a	n/a	-US$214m
Dec 31 2023	US$6m	US$805k	-US$186m
Sep 30 2023	n/a	n/a	-US$166m
Jun 30 2023	n/a	n/a	-US$151m
Mar 31 2023	n/a	n/a	-US$165m
Dec 31 2022	US$7m	US$782k	-US$320m
Sep 30 2022	n/a	n/a	-US$371m
Jun 30 2022	n/a	n/a	-US$403m
Mar 31 2022	n/a	n/a	-US$411m
Dec 31 2021	US$11m	US$745k	-US$270m
Sep 30 2021	n/a	n/a	-US$220m
Jun 30 2021	n/a	n/a	-US$199m
Mar 31 2021	n/a	n/a	-US$181m
Dec 31 2020	US$14m	US$710k	-US$153m
Sep 30 2020	n/a	n/a	-US$134m
Jun 30 2020	n/a	n/a	-US$113m
Mar 31 2020	n/a	n/a	-US$93m
Dec 31 2019	US$13m	US$600k	-US$85m
Sep 30 2019	n/a	n/a	-US$75m
Jun 30 2019	n/a	n/a	-US$65m
Mar 31 2019	n/a	n/a	-US$55m
Dec 31 2018	US$8m	US$500k	-US$44m
Sep 30 2018	n/a	n/a	-US$37m
Jun 30 2018	n/a	n/a	-US$32m
Mar 31 2018	n/a	n/a	-US$27m
Dec 31 2017	US$1m	US$300k	-US$24m

보상 대 시장: Robert 의 총 보상 ($USD 6.30M )은 US 시장( $USD 649.07K ).

보상과 수익: Robert 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Robert Alexander (54 yo)

7.6yrs

테뉴어

US$6,299,426

보상

Dr. Robert Alexander, Ph D., had been an Independent Director of Allena Pharmaceuticals, Inc. since June 2016 until 2022. He has been the Chief Executive Officer of Allakos Inc. since April 2017 and served...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Alexander	CEO & Director	7.6yrs	US$6.30m	0.80% $ 623.7k
Adam Tomasi	President	5.3yrs	US$4.27m	0.34% $ 269.7k
Baird Radford	Chief Financial Officer	3.6yrs	US$2.74m	데이터 없음
Mary Cromwell	Chief Technical Officer	1.3yrs	데이터 없음	데이터 없음
Chin Lee	Chief Medical Officer	less than a year	데이터 없음	0.32% $ 250.4k
Alan Chang	Director of Medical Affairs & Data Analytics	no data	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: ALLK 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Alexander	CEO & Director	7.5yrs	US$6.30m	0.80% $ 623.7k
Paul Walker	Independent Director	7yrs	US$387.12k	0% $ 0
Steven James	Independent Director	8.6yrs	US$387.12k	0% $ 0
Neil Graham	Independent Director	1.3yrs	US$378.28k	0% $ 0
Amy Ladd	Independent Director	2.3yrs	US$372.12k	0% $ 0
Robert Andreatta	Independent Director	6.4yrs	US$389.62k	0% $ 0
Bruce Bochner	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Robert Schleimer	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Dolca Thomas	Independent Director	1.3yrs	US$732.48k	0.043% $ 33.9k

6.4yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: ALLK 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

Allakos 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Allakos Inc., Annual General Meeting, May 24, 2024

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Allakos Inc. Appoints Neil Graham to its Board of Directors

Allakos Inc. Announces Board Appointments

Recent updates

Allakos Runs Up Into A Near-Term Catalyst

Allakos Inc. Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully

Allakos Inc. Receives A Letter from the Listing Qualifications Staff (The Staff") of the Nasdaq Stock Market LLC

New minor risk - Shareholder dilution

New major risk - Financial position

Allakos Inc.(NasdaqGS:ALLK) dropped from Russell Small Cap Comp Value Index

Allakos Inc. Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

Allakos Inc., Annual General Meeting, May 24, 2024

New minor risk - Market cap size

CEO & Director notifies of intention to sell stock

Allakos Inc. Announces Publication Highlighting AK006 Mast Cell Inhibition

New minor risk - Market cap size

Allakos Announces Restructuring to Focus on Development of AK006

New major risk - Share price stability

Price target decreased by 32% to US$6.50

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

Price target decreased by 8.4% to US$9.08

CEO & Director notifies of intention to sell stock

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

Price target increased by 7.4% to US$8.67

CEO & Director notifies of intention to sell stock

Allakos Inc. Appoints Neil Graham to its Board of Directors

Allakos Inc. Announces Board Appointments

Allakos Inc. Announces Board of Directors Appointment

Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth

CEO & Director notifies of intention to sell stock

Price target increased by 17% to US$8.50

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Price target decreased by 19% to US$5.69

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

CEO & Director notifies of intention to sell stock

Price target increased to US$7.06

Insufficient new directors

Price target increased to US$7.06

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Allakos prices ~$150M underwritten offering

Price target decreased to US$6.56

Allakos Inc. Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

Allakos falls as lead asset offers mixed results in late-stage trial

Price target decreased to US$7.11

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Allakos Inc. Announces the Appointment of Dr. Amy Ladd to Its Board of Directors

Allakos Inc.(NasdaqGS:ALLK) dropped from Russell 2000 Growth Index

Price target decreased to US$10.28

Insufficient new directors

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Allakos Inc. Announces Management Changes

Allakos Inc., Annual General Meeting, May 25, 2022

Allakos Inc. to Hold an End-Of-Phase 2 Meeting with the FDA During Second Quarter of 2022

Price target decreased to US$19.38

Allakos: Sad End To A Promising Asset

Price target decreased to US$51.44

Allakos Inc. Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

Allakos Inc. Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Independent Director exercised options and sold US$430k worth of stock

President & COO exercised options to buy US$6.2m worth of stock.

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Allakos Provides Business Update

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

Insufficient new directors

President & COO exercised options and sold US$3.6m worth of stock

CEO & Director exercised options and sold US$4.0m worth of stock

CEO & Director recently sold US$2.0m worth of stock

Allakos Inc. Completes Enrollment in Phase 3 Study of Lirentelimab in Patients with Eosinophilic Gastritis